Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025)
Inhibikase Therapeutics (IKT) reported Capital Expenditures of $13,399 for FY2025.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025) Analysis & Trends
- Capital Expenditures has a three-year compound annual growth rate of -62.0% (FY2022 to FY2025).
- According to Business Quant data, Capital Expenditures came in at $14,238 in FY2023 (-94.1%) and $243,255 in FY2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,130.22 Bn | 1,098.81 Bn | 19.71 Bn | 2.93 Bn |
| 2 | Johnson & Johnson | 613.62 Bn | 532.15 Bn | 17.26 Bn | 1.32 Bn |
| 3 | AbbVie | 501.46 Bn | 474.57 Bn | 12.70 Bn | 322.00 Mn |
| 4 | Merck | 366.84 Bn | 321.22 Bn | 12.21 Bn | 893.00 Mn |
| 5 | Novartis Ag | 297.85 Bn | 261.84 Bn | 11.24 Bn | 321.00 Mn |
| 6 | Astrazeneca | 261.66 Bn | 235.34 Bn | 12.86 Bn | 1.86 Bn |
| 7 | Amgen | 235.39 Bn | 190.79 Bn | 7.24 Bn | 513.00 Mn |
| 8 | Gilead Sciences | 190.66 Bn | 164.86 Bn | 6.22 Bn | 140.00 Mn |
| 9 | Pfizer | 169.57 Bn | 116.22 Bn | 10.94 Bn | 533.00 Mn |
| 10 | Inhibikase Therapeutics | 295.90 Mn | -289.58 Mn | - | - |
API Access
Inhibikase Therapeutics Capital Expenditures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "capital-expenditures", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();